Protective role of adiponectin on endothelial dysfunction induced by AGEs: A clinical and experimental approach

Microvascular Research

Volumn 82, Issue 1, 2011, Pages 73-76

  Del Turco, Serena ^a   Navarra, Teresa ^a   Gastaldelli, Amalia ^a   Basta, Giuseppina ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; UMBILICAL VEIN ENDOTHELIAL CELL;

ADIPONECTIN; ADULT; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; E-SELECTIN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE TOLERANCE TEST; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; LYSINE; MALE; MIDDLE AGED; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79957851638     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2011.03.003     Document Type: Article

References (26)

1. Adamczak M., Wiecek A., Funahashi T., Chudek J., Kokot F., Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am. J. Hypertens. 2003, 16:72-75.
2. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
3. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., Kislinger T., Stern D.M., Schmidt A.M., De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105:816-822.
4. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 2004, 63:582-592.
5. Basta G., Sironi A.M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., Natali A., Ferrannini E., Gastaldelli A. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab. 2006, 91:4628-4634.
6. Del Turco S., Basta G., Lazzerini G., Evangelista M., Rainaldi G., Tanganelli P., Camera M., Tremoli E., De Caterina R. Parallel decrease of tissue factor surface exposure and increase of tissue factor microparticle release by the n-3 fatty acid docosahexaenoate in endothelial cells. Thromb. Haemost. 2007, 98:210-219.
7. Fernandez-Real J.M., Castro A., Vazquez G., Casamitjana R., Lopez-Bermejo A., Penarroja G., Ricart W. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 2004, 27:739-745.
8. Kaloudi O., Basta G., Perfetto F., Bartoli F., Del Rosso A., Miniati I., Conforti M.L., Generini S., Guiducci S., Abbate R., Pignone A., Castellani S., Livi R., De Caterina R., Matucci-Cerinic M. Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis. Rheumatol. Oxford. 2007, 46:412-416.
9. Kim J.Y., van de Wall E., Laplante M., Azzara A., Trujillo M.E., Hofmann S.M., Schraw T., Durand J.L., Li H., Li G., Jelicks L.A., Mehler M.F., Hui D.Y., Deshaies Y., Shulman G.I., Schwartz G.J., Scherer P.E. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 2007, 117:2621-2637.
10. Lazzerini G., Del Turco S., Basta G., O'Loghlen A., Zampolli A., Caterina R.D. Prominent role of NF-kappaB in the induction of endothelial activation by endogenous nitric oxide inhibition. Nitric Oxide 2009, 21:184-191.
11. Li S., Shin H.J., Ding E.L., van Dam R.M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. Jama. 2009, 302:179-188.
12. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
13. Massaro M., Basta G., Lazzerini G., Carluccio M.A., Bosetti F., Solaini G., Visioli F., Paolicchi A., De Caterina R. Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. Thromb. Haemost. 2002, 88:335-344.
14. Meyers M.R., Gokce N. Endothelial dysfunction in obesity: etiological role in atherosclerosis. Curr. Opin. Endocrinol. Diab. Obes. 2007, 14:365-369.
15. Norata G.D., Garlaschelli K., Grigore L., Tibolla G., Raselli S., Redaelli L., Buccianti G., Catapano A.L. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr. Metab. Cardiovasc. Dis. 2009, 19:129-134.
16. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., Hotta K., Nishida M., Takahashi M., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
17. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
18. Ouedraogo R., Wu X., Xu S.Q., Fuchsel L., Motoshima H., Mahadev K., Hough K., Scalia R., Goldstein B.J. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006, 55:1840-1846.
19. Pierce G.L., Beske S.D., Lawson B.R., Southall K.L., Benay F.J., Donato A.J., Seals D.R. Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight/obese adults. Hypertension 2008, 52:72-79.
20. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
21. Plant S., Shand B., Elder P., Scott R. Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diab. Vasc. Dis. Res. 2008, 5:102-108.
22. Shimabukuro M., Higa N., Asahi T., Oshiro Y., Takasu N., Tagawa T., Ueda S., Shimomura I., Funahashi T., Matsuzawa Y. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J. Clin. Endocrinol. Metab. 2003, 88:3236-3240.
23. Stirban A., Negrean M., Gotting C., Uribarri J., Gawlowski T., Stratmann B., Kleesiek K., Koschinsky T., Vlassara H., Tschoepe D. Dietary advanced glycation endproducts and oxidative stress: in vivo effects on endothelial function and adipokines. Ann. NY Acad. Sci. 2008, 1126:276-279.
24. Unno Y., Sakai M., Sakamoto Y., Kuniyasu A., Nakayama H., Nagai R., Horiuchi S. Advanced glycation end products-modified proteins and oxidized LDL mediate down-regulation of leptin in mouse adipocytes via CD36. Biochem. Biophys. Res. Commun. 2004, 325:151-156.
25. Williams I.L., Wheatcroft S.B., Shah A.M., Kearney M.T. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int. J. Obes. Relat. Metab. Disord. 2002, 26:754-764.
26. Yonekura H., Yamamoto Y., Sakurai S., Watanabe T., Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J. Pharmacol. Sci. 2005, 97:305-311.